Harmonica consensus, controversies, and future directions in radiotherapy for pediatric Wilms tumors
Authors
McAleer, M. F.Melchior, P.
Parkes, J.
Pater, L.
Rübe, C.
Saunders, Daniel
Paulino, A. C.
Janssens, G. O.
Kalapurakal, J.
Affiliation
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAIssue Date
2022
Metadata
Show full item recordAbstract
Radiotherapy (RT) is essential for multimodality treatment of pediatric renal tumors, particularly in higher-risk and metastatic disease. Despite decades of use, particularly for Wilms tumor, there remain controversies regarding RT indications, timing, dose, and targets. To align global management, we address these issues in this international HARMONIsation and CollAboration (HARMONICA) project. There are multiple knowledge gaps and opportunities for future research including: (1) utilization of advanced RT technologies, including intensity-modulated RT, proton beam therapy, combined with image-guided RT to reduce target volumes; (2) impact of molecular biomarkers including loss of heterozygosity at 1p, 16q, and 1q gain on RT indications; (3) mitigation of reproductive toxicity following RT; (4) promotion of RT late effects research; and (5) support to overcome challenges in RT utilization in low- and middle-income countries where 90% of the world's children reside. Here, we outline current status and future directions for RT in pediatric renal tumors.Citation
McAleer MF, Melchior P, Parkes J, Pater L, Rübe C, Saunders D, et al. Harmonica consensus, controversies, and future directions in radiotherapy for pediatric Wilms tumors. Pediatric blood & cancer. 2022 Dec 8:e30090. PubMed PMID: 36482883. Epub 2022/12/10. eng.Journal
Pediatric Blood and CancerDOI
10.1002/pbc.30090PubMed ID
36482883Additional Links
https://dx.doi.org/10.1002/pbc.30090Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1002/pbc.30090